Genprex (NASDAQ:GNPX) Posts Earnings Results

Genprex (NASDAQ:GNPX) issued its quarterly earnings results on Friday. The company reported ($9.40) earnings per share for the quarter, Zacks reports.

Genprex Stock Performance

Shares of NASDAQ:GNPX traded down $0.56 during mid-day trading on Friday, hitting $4.31. The stock had a trading volume of 87,008 shares, compared to its average volume of 61,742. The company’s 50 day moving average is $9.69 and its 200-day moving average is $25.41. Genprex has a 12-month low of $4.00 and a 12-month high of $1,210.00. The company has a market cap of $2.15 million, a PE ratio of -0.01 and a beta of -0.88.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on GNPX shares. Wall Street Zen upgraded shares of Genprex from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Genprex in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Institutional Trading of Genprex

A hedge fund recently raised its position in Genprex stock. Susquehanna International Group LLP increased its holdings in shares of Genprex (NASDAQ:GNPX) by 11.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 340,056 shares of the company’s stock after buying an additional 35,661 shares during the quarter. Susquehanna International Group LLP owned 27.20% of Genprex worth $58,000 as of its most recent filing with the Securities and Exchange Commission. 14.05% of the stock is currently owned by institutional investors and hedge funds.

Genprex Company Profile

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.